Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Free Cash Flow (2019 - 2025)

Bioadaptives' Free Cash Flow history spans 7 years, with the latest figure at -$151309.0 for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 168.55% year-over-year to -$151309.0; the TTM value through Sep 2025 reached -$460735.0, down 91.75%, while the annual FY2024 figure was -$249517.0, 11.5% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$151309.0 at Bioadaptives, down from -$110982.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$19461.0 in Q1 2023 and bottomed at -$151309.0 in Q3 2025.
  • The 5-year median for Free Cash Flow is -$56867.0 (2023), against an average of -$64178.8.
  • The largest annual shift saw Free Cash Flow plummeted 258.98% in 2021 before it soared 68.18% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$35403.0 in 2021, then increased by 22.31% to -$27504.0 in 2022, then crashed by 231.94% to -$91296.0 in 2023, then fell by 10.12% to -$100538.0 in 2024, then plummeted by 50.5% to -$151309.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Free Cash Flow are -$151309.0 (Q3 2025), -$110982.0 (Q2 2025), and -$97906.0 (Q1 2025).